Understanding the Difference Between Anticoagulants and Antiplatelets

About this course

In the realm of cardiovascular health, blood thinners, such as anticoagulants and antiplatelets, play a crucial role in patient care. Contrary to their name, these drugs do not actually “thin” the blood. Instead, they target different components within blood coagulation and platelet aggregation, two processes that contribute to the formation and growth of thrombi. While anticoagulants and antiplatelets have a similar overall effect, they have varying mechanisms of action, dosages, and interactions. Understanding these variances is essential for healthcare providers to tailor treatment and for patients to be well-informed about their therapy. This course aims to provide an overview of the distinctions between anticoagulant and antiplatelet medications, explain their respective roles in managing different conditions, and highlight the considerations for their safe and effective use.

Learning objectives

• Review the pathophysiology of clot formation through the blood coagulation cascade and platelet aggregation.
• Understand the indications for antiplatelet and anticoagulant use.
• Review anticoagulants and antiplatelets, including mechanisms of action, medication types, doses, side effects, and reversal agents.
• Review common laboratory findings for patients on antiplatelet and anticoagulants.
• Identify herbal supplements that can increase the risk of bleeding.
• Review patient and nursing considerations for antiplatelet and anticoagulant therapy.

Course outline

23 sections · finish in any order across devices

1. 1

   Introduction

   In the realm of cardiovascular health, blood thinners, such as anticoagulants and antiplatelets, play a crucial role in patient care.1 Contrary to their name, these drugs do not actually “thin” the blood. Instead, they target different components within blood coagulation and platelet aggregation, tw

   4 min

2. 2

   Understanding Normal Clot Formation

   To grasp the mechanisms of action for anticoagulants and antiplatelets, it is important to have a basic understanding of the blood coagulation cascade and platelet aggregation. The blood coagulation cascade is a complex series of events that helps stop bleeding after vascular injury.3 Numerous enzym

   4 min

3. 3

   Anticoagulants

   Anticoagulants target various stages of the blood coagulation cascade and include unfractionated heparin, low molecular weight heparins (LMWHs), vitamin K antagonists, direct thrombin inhibitors, and direct Factor Xa inhibitors.4 Unfractionated heparin is the first anticoagulant ever used. Discovere

   4 min

4. 4

   Antiplatelets

   Antiplatelets prevent blood clots by inhibiting platelets from activating, aggregating, or both. This reduces the stability of forming blood clots, thus reducing the risk of thrombotic events.9 Antiplatelets include aspirin, adenosine diphosphate (ADP) inhibitors, glycoprotein IIb/IIIa inhibitors, p

   4 min

5. 5

   Indications for Anticoagulant Use

   Anticoagulants are used in cases where the clotting process must be broadly inhibited within blood vessels, such as in the veins or the heart. They are effective for treatment, long-term management, and as a prophylaxis.15 As a treatment, anticoagulants dissolve the existing clot, prevent its enlarg

   4 min

6. 6

   Deep Vein Thrombosis (DVT)

   Deep vein thrombosis (DVT) is blood clot development in a deep vein, most commonly in the legs.16 This condition occurs when blood flow is impaired, leading to clot formation in the veins. Deep vein thrombosis can be caused by prolonged immobility, such as during long flights or bed rest, trauma to

   4 min

7. 7

   Pulmonary Embolism (PE)

   Pulmonary Embolism (PE) is caused by a blood clot that has traveled to the blood vessels of the lungs, blocking a pulmonary artery or one of its branches. The blockage impairs blood flow to the lung tissue, reducing oxygen exchange and potentially causing damage to the lungs and heart. Pulmonary emb

   4 min

8. 8

   Atrial Fibrillation (AF)

   Atrial fibrillation (AF) is a common type of arrhythmia characterized by an irregular heartbeat originating from the atria, the heart’s upper chambers.22 This condition can be intermittent (paroxysmal), persistent, or permanent. Regardless of the type, AF disrupts the heart’s normal rhythm, potentia

   4 min

9. 9

   Post-Surgical Prophylaxis

   Post-surgical prophylaxis refers to the preventive measures to reduce the risk of thromboembolic events following surgical procedures.24 Complications may arise as a result of surgery, especially in surgeries involving the lower limbs or pelvis, which can lead to prolonged immobility and increase th

   4 min

10. 10

    Mechanical Heart Valves

    Mechanical heart valves are artificial devices constructed from durable materials such as carbon or titanium designed to mimic the function of natural valves.25 They replace damaged or diseased heart valves to ensure proper blood flows through the heart chambers and prevents regurgitation. Mechanica

    4 min

11. 11

    Indications for Antiplatelet Use

    Antiplatelets are used in cases where the primary issue is platelet aggregation rather than the broader clotting cascade. They are particularly effective for preventing arterial clots.9 Hence, they are commonly used in both primary and secondary prevention strategies for cardiovascular events, as we

    4 min

12. 12

    Primary Prevention

    Antiplatelets are often prescribed for individuals at high risk of cardiovascular events but who have not yet experienced an event.9 This initiative-taking approach is known as primary prevention. It aims to prevent the initial occurrence of cardiovascular events in high-risk patients. Patients cons

    4 min

13. 13

    Secondary Prevention

    For patients who have already had a cardiovascular event, such as a myocardial infarction (heart attack) or ischemic stroke, antiplatelet therapy is essential to prevent recurrence.9 These medications work by inhibiting platelet activation and aggregation, reducing the risk of new clot formation tha

    4 min

14. 14

    Acute Coronary Syndrome (ACS)

    Acute Coronary Syndrome (ACS) encompasses three serious conditions caused by a sudden drop or blockage of blood flow to the heart.30 These conditions include unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). Acute Coronary Syndrome typi

    4 min

15. 15

    Peripheral Artery Disease (PAD)

    Peripheral Artery Disease (PAD) is a circulatory problem that causes reduced blood flow to the limbs, most commonly the legs.31 PAD is primarily caused by atherosclerosis, which narrows the arteries. Other causative factors include high blood pressure, high cholesterol, advanced age, obesity, smokin

    4 min

16. 16

    Postoperative Management

    Cardiovascular surgeries like coronary artery bypass grafting (CABG), carotid endarterectomy, and percutaneous coronary interventions (PCI) are necessary for improving blood flow and reducing ischemic risk.32 However, they inherently disrupt the vascular endothelium, creating a pro-thrombotic enviro

    4 min

17. 17

    Common Side Effects of Blood Thinners

    While essential in preventing and treating thromboembolic events, blood thinners can cause several common side effects.33 The side effects include bleeding, gastrointestinal discomfort, possible decrease in appetite, weight loss, headaches, and dizziness. Bleeding is one of the most prevalent issues

    4 min

18. 18

    Laboratory Findings

    Monitoring the efficacy and safety of blood thinners involves several key laboratory tests:

    4 min

19. 19

    Treatment Options for Abnormal Lab Findings

    When laboratory findings indicate abnormal levels in patients on blood thinners, prompt and appropriate interventions are crucial to manage risks and ensure patient safety. For abnormal INR in patients on warfarin, treatment options depend on the degree of INR elevation and the presence of bleeding

    4 min

20. 20

    Herbal Supplements and Bleeding Risk

    Certain herbal supplements can interact with blood thinners, potentially increasing the risk of bleeding. These include: 43

    4 min

21. 21

    Patient Considerations

    For patients on blood thinner therapy, certain considerations must be considered.44 The most important is adherence. Patients should follow the medication regimen precisely as directed by their healthcare provider. This means taking the correct dose at the right time. To support adherence, patients

    4 min

22. 22

    Nursing Considerations

    When managing patients on anticoagulant and antiplatelet therapy, nurses must be vigilant in monitoring for various complications to ensure safety and efficacy.45 One of the primary concerns is bleeding, as anticoagulants and antiplatelet increase the risk of both external and internal bleeding. Nur

    4 min

23. 23

    Conclusion

    In cardiovascular care, understanding the distinct roles and mechanisms of anticoagulants and antiplatelets is essential for effective treatment and prevention of thrombotic events. While both classes of drugs aim to mitigate the risk of blood clots, they operate through different pathways. Each typ

    4 min

This course satisfies

Requirement summaries come from our state requirement records. Always confirm details with your board before you renew.

References and resources

• Medline Plus. (2019). Blood Thinners. Medlineplus.gov; National Library of Medicine. https://medlineplus.gov/bloodthinners.htm
• Govindarajan, V., Rakesh, V., Reifman, J., & Mitrophanov, A. Y. (2016). Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions. Biophysical Journal, 110(8), 1869-1885. https://doi.org/10.1016/j.bpj.2016.03.010
• Al-Koussa, H., AlZaim, I., & El-Sabban, M. E. (2022). Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders. Journal of Clinical Medicine, 11(16). https://doi.org/10.3390/jcm11164932
• Heestermans, M., Poenou, G., Hamzeh-Cognasse, H., Cognasse, F., & Bertoletti, L. (2022). Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells, 11(20). https://doi.org/10.3390/cells11203214
• Coumadin (warfarin sodium) tablets Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf
• PRADAXA (dabigatran etexilate) capsules, for oral use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022512s039lbl.pdf
• XARELTO (rivaroxaban) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf
• ELIQUIS (apixaban) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
• Jourdi, G., Lordkipanidzé, M., Philippe, A., Bachelot-Loza, C., & Gaussem, P. (2021). Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 22(23). https://doi.org/10.3390/ijms222313079
• PLAVIX (clopidogrel bisulfate) tablets, for oral use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020839s070lbl.pdf
• BRILINTA (ticagrelor) tablets, for oral use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf
• Integrilin (eptifibatide) injection label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf
• AGGRASTAT (tirofiban hydrochloride) injection, for intravenous use label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020912s024,020913s022lbl.pdf
• PLETAL (cilostazol) tablets, for oral use Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020863s024lbl.pdf
• Anticoagulant Therapy - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/anticoagulant-therapy
• Alexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. E. (2021). Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review. Cureus, 13(10). https://doi.org/10.7759/cureus.18992
• Medscape. (2019, September 28). Heparin dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/calciparine-monoparin-heparin-342169
• Medscape. (2019, September 28). Lovenox (enoxaparin) dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/lovenox-enoxaparin-342174
• Medscape. (2019, October 14). Xarelto (rivaroxaban) dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/xarelto-rivaroxaban-999670
• Medscape. (2019, December 9). Eliquis (apixaban) dosing, indications, interactions, adverse effects, and more. Medscape.com. https://reference.medscape.com/drug/eliquis-apixaban-999805
• Naoum, J. J. (2024). Anticoagulation Management Post Pulmonary Embolism. Methodist DeBakey Cardiovascular Journal, 20(3), 27-35. https://doi.org/10.14797/mdcvj.1338
• Tai, W. (2023). Atrial Fibrillation: A Common Cause of Stroke. Delaware Journal of Public Health, 9(3), 12-15. https://doi.org/10.32481/djph.2023.08.004
• Coumadin, Jantoven (warfarin) dosing, indications, interactions, adverse effects, and more. (n.d.). Reference.medscape.com. https://reference.medscape.com/drug/coumadin-jantoven-warfarin-342182
• Tun, H. N., Kyaw, M. T., Rafflenbeul, E., & Suástegui, X. L. (2022). Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis. European Cardiology Review, 17. https://doi.org/10.15420/ecr.2021.55
• Langenaeken, T., Vanoppen, A., Janssens, F., Tanghe, L., Verbrugghe, P., Rega, F., & Meuris, B. (2023). DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives. Journal of Clinical Medicine, 12(15). https://doi.org/10.3390/jcm12154984
• World Health Organization. (2021, June 11). Cardiovascular diseases (CVDs). World Health Organization; World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
• Medscape. (n.d.). Bayer Buffered Aspirin, Vazalore (aspirin) dosing, indications, interactions, adverse effects, and more. Reference.medscape.com. https://reference.medscape.com/drug/bayer-vazalore-aspirin-343279
• Plavix (clopidogrel) dosing, indications, interactions, adverse effects, and more. (n.d.). Reference.medscape.com. https://reference.medscape.com/drug/plavix-clopidogrel-342141
• Brilinta (ticagrelor) dosing, indications, interactions, adverse effects, and more. (n.d.). Reference.medscape.com. https://reference.medscape.com/drug/brilinta-ticagrelor-999674
• Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2008). Acute coronary syndromes. Lancet (London, England), 399(10332), 1347-1358. https://doi.org/10.1016/S0140-6736(21)02391-6
• Soyoye, D. O., Abiodun, O. O., Ikem, R. T., Kolawole, B. A., & Akintomide, A. O. (2021). Diabetes and peripheral artery disease: A review. World Journal of Diabetes, 12(6), 827-838. https://doi.org/10.4239/wjd.v12.i6.827
• Mahmood, H., Siddique, I., & McKechnie, A. (2019). Antiplatelet drugs: A review of pharmacology and the perioperative management of patients in oral and maxillofacial surgery. Annals of The Royal College of Surgeons of England, 102(1), 9-13. https://doi.org/10.1308/rcsann.2019.0154
• Harter, K., Levine, M., & Henderson, S. O. (2014). Anticoagulation Drug Therapy: A Review. Western Journal of Emergency Medicine, 16(1), 11-17. https://doi.org/10.5811/westjem.2014.12.22933
• Prothrombin Time (PT) and International Normalized Ratio (INR) - Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/PT-1
• International Normalized Ratio - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/nursing-and-health-professions/international-normalized-ratio
• Activated Partial Thromboplastin Time - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/engineering/activated-partial-thromboplastin-time
• Activated Partial Thromboplastin Time (PTT) - Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/PTT-1
• Heparin Anti-Xa - Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/HPXA
• Platelet Count - Hunterdon Medical Center. (2024). Testcatalog.org. https://hmc.testcatalog.org/show/PLT-1
• Protamine Sulfate - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/protamine-sulfate
• Momin, J. H., Candidate, P., & Hughes, G. J. (2019). Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants. Pharmacy and Therapeutics, 44(9), 530. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705484/
• Thrombocyte Transfusion - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/thrombocyte-transfusion
• Abebe, W. (2019). Review of herbal medications with the potential to cause bleeding: Dental implications, and risk prediction and prevention avenues. The EPMA Journal, 10(1), 51-64. https://doi.org/10.1007/s13167-018-0158-2
• Blood Thinner Pills: Your Guide to Using Them Safely. (n.d.). Www.ahrq.gov. https://www.ahrq.gov/patients-consumers/diagnosis-treatment/treatments/btpills/btpills.html
• Palomo Lara, J. C., March-Cerdà, J. C., Ponce-Blandón, J. A., Pabón-Carrasco, M., & Jiménez-Picón, N. (2024). Effectiveness and Health Outcomes of Collaborative Nurse Prescribing for Patients Anticoagulated with Antivitamin K in Primary Care: A Study Protocol. Healthcare, 12(3). https://doi.org/10.3390/healthcare12030347
• Hawes, E. M. (2018). Patient Education on Oral Anticoagulation. Pharmacy: Journal of Pharmacy Education and Practice, 6(2). https://doi.org/10.3390/pharmacy6020034

Update history